CalciMedica, Inc. (CALC) stock
CALCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.22+0.03 (+2.52%)
Close on Nov 17, 2026Market cap $41.65MP/E –Yield –
CalciMedica operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CalciMedica's operating income for the twelve months ending Jun 30, 2026 was -$19.63M. For fiscal 2025 it was -$23.12M. The highest annual figure on record is -$14.19M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$23.12M | – |
| FY2024 | Dec 31, 2024 | -$24.20M | – |
| FY2023 | Dec 31, 2023 | -$38.08M | – |
| FY2022 | Dec 31, 2022 | -$14.19M | – |
| FY2021 | Dec 31, 2021 | -$35.95M | – |
| FY2020 | Dec 31, 2020 | -$29.83M | – |
| FY2019 | Dec 31, 2019 | -$37.50M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.01M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.61M | – |
| Q4 FY2025 | Dec 31, 2025 | -$4.39M | – |
| Q3 FY2025 | Sep 30, 2025 | -$5.62M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.62M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.50M | – |
| Q4 FY2024 | Dec 31, 2024 | -$6.17M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.74M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.53M | – |
| Q1 FY2024 | Mar 31, 2024 | -$5.77M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.32M | – |
| Q3 FY2023 | Sep 30, 2023 | -$4.83M | – |
| Q2 FY2023 | Jun 30, 2023 | -$6.58M | – |
| Q1 FY2023 | Mar 31, 2023 | -$22.34M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.59M | – |
| Q1 FY2022 | Mar 31, 2022 | -$4.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$8.70M | – |
| Q3 FY2021 | Sep 30, 2021 | -$8.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$7.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$11.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.18M | – |
| Q3 FY2020 | Sep 30, 2020 | -$6.82M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.80M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.53M | – |
| Q3 FY2019 | Sep 30, 2019 | -$10.37M | – |
See a number that looks wrong?